Gartner Inc vs Zoetis Inc — how do they compare? Gartner Inc trades at $195.41 (market cap $12.34B), while Zoetis Inc trades at $73.02 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.4× Gartner Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Zoetis Inc for 70 Days on average.
| IT | ZTS | |
|---|---|---|
Market Cap | $12.34B | $30.20B |
Volume | 919,809 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $258.17 | $147.53 |
52-Week Low | $125.68 | $69.09 |
Typical Hold Time | 64 Days | 70 Days |
Enterprise Value | $14.08B | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $185.77, up 0.46% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company shows robust profitability with a 69.63% gross margin and 12% net income margin, though 2025 net income declined to $729 million. Recent news highlights AI advisory demand and a shareholder investigation, while analyst consensus is mixed with a $174.63 price target below the current price.
Outlook remains supported by high ROE and consulting industry growth, but risks include the shareholder fiduciary probe and volatile cash flows. The stock faces resistance near $188, with valuation metrics like P/E of 17.57 appearing reasonable if earnings stabilize.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Trailing returns across standard periods
Latest headlines on both assets
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →